AU2019354965B2 - Improvement of glymphatic delivery by manipulating plasma osmolarity - Google Patents

Improvement of glymphatic delivery by manipulating plasma osmolarity Download PDF

Info

Publication number
AU2019354965B2
AU2019354965B2 AU2019354965A AU2019354965A AU2019354965B2 AU 2019354965 B2 AU2019354965 B2 AU 2019354965B2 AU 2019354965 A AU2019354965 A AU 2019354965A AU 2019354965 A AU2019354965 A AU 2019354965A AU 2019354965 B2 AU2019354965 B2 AU 2019354965B2
Authority
AU
Australia
Prior art keywords
brain
composition
antibody
influx
glymphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019354965A
Other languages
English (en)
Other versions
AU2019354965A1 (en
Inventor
Humberto MESTRE
Maiken Nedergaard
Benjamin PLOG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of AU2019354965A1 publication Critical patent/AU2019354965A1/en
Application granted granted Critical
Publication of AU2019354965B2 publication Critical patent/AU2019354965B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2019354965A 2018-10-04 2019-09-30 Improvement of glymphatic delivery by manipulating plasma osmolarity Active AU2019354965B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741295P 2018-10-04 2018-10-04
US62/741,295 2018-10-04
PCT/US2019/053808 WO2020072357A1 (en) 2018-10-04 2019-09-30 Improvement of glymphatic delivery by manipulating plasma osmolarity

Publications (2)

Publication Number Publication Date
AU2019354965A1 AU2019354965A1 (en) 2021-05-06
AU2019354965B2 true AU2019354965B2 (en) 2025-03-27

Family

ID=68502006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019354965A Active AU2019354965B2 (en) 2018-10-04 2019-09-30 Improvement of glymphatic delivery by manipulating plasma osmolarity

Country Status (8)

Country Link
US (1) US12311035B2 (https=)
EP (1) EP3860564A1 (https=)
JP (2) JP7611149B2 (https=)
KR (1) KR20210100086A (https=)
CN (1) CN113226283A (https=)
AU (1) AU2019354965B2 (https=)
CA (1) CA3115071A1 (https=)
WO (1) WO2020072357A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3188212A1 (en) * 2020-08-03 2022-02-10 John Pile-Spellman Devices and methods for trans-arterial osmotic embolization of pathological tissue
US20250235554A1 (en) * 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux
US12483569B2 (en) 2024-03-28 2025-11-25 Bank Of America Corporation System and method for identifying unauthorized data traffic in a computing network
WO2025250457A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170105927A1 (en) * 2015-10-15 2017-04-20 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2017210343A1 (en) * 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
WO2018015467A1 (en) * 2016-07-20 2018-01-25 P&X Medical Nv Compounds for use in methods for treating glaucoma and retinal diseases
US20180271796A1 (en) * 2015-09-11 2018-09-27 The Johns Hopkins University Compositions and methods to improve nanoparticle distribution within the brain interstitium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
DE69636937T3 (de) 1995-12-15 2011-01-05 Virxsys Corp. Durch trans-spaltung erhaltene therapeutische molekule
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1429805A4 (en) 2001-08-17 2005-09-21 Lilly Co Eli USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B)
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8801541B2 (en) 2007-09-27 2014-08-12 Taylor Made Golf Company, Inc. Golf club
WO2006014638A2 (en) * 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
US20060246075A1 (en) 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
MX350378B (es) 2012-01-10 2017-09-05 Biogen Ma Inc Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
EP2964270A4 (en) * 2013-02-21 2017-03-22 University Of Rochester Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
CA3010738A1 (en) * 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180271796A1 (en) * 2015-09-11 2018-09-27 The Johns Hopkins University Compositions and methods to improve nanoparticle distribution within the brain interstitium
US20170105927A1 (en) * 2015-10-15 2017-04-20 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2017210343A1 (en) * 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
WO2018015467A1 (en) * 2016-07-20 2018-01-25 P&X Medical Nv Compounds for use in methods for treating glaucoma and retinal diseases

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ADAM J RUSSAK ET AL: vol. 86, no. 16 suppl. 1, 20 April 2016 (2016-04-20), pages P5.214, Retrieved from the Internet [retrieved on 20160404] *
ADAM J RUSSAK ET AL: vol. 86, no. 16 suppl. 1, 20 April 2016 (2016-04-20), pages P5.214, Retrieved from the Internet <URL:https://n.neurology.org/content/86/16_Supplement/P5.214> [retrieved on 20160404] *
BENJAMIN A. PLOG ET AL: "The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future", ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, vol. 13, no. 1, (2018-01-24), pages 379 - 394, *
D THAKKER ET AL: "Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice", SYNLETT, GEORG THIEME VERLAG, DE, vol. 106, no. 11, (2009), pages 4501 - 4506, *
H BENVENISTE ET AL: "Anesthesia with Dexmedetomidine and Low-dose Isoflurane Increases Solute Transport via the Glymphatic Pathway in Rat Brain When Compared with High-dose Isoflurane :", ANESTHESIOLOGY. vol. 127(6), (2017), p 976 - 988, *
HORIGUCHI ET AL: "Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation", ALCOHOL, vol. 41, no. 4, (2007), pages 271 - 280, DOI: 10.1016/J.ALCOHOL.2007.04.008 *
IBEN LUNDGAARD ET AL: "Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function", SCIENTIFIC REPORTS, vol. 8, no. 1, 2 February 2018 (2018-02-02), DOI: 10.1038/s41598-018-20424-y *
J. J. ILIFF ET AL: "Cerebral Arterial Pulsation Drives Paravascular CSF-Interstitial Fluid Exchange in the Murine Brain", THE JOURNAL OF NEUROSCIENCE, vol. 33, no. 46, (2013), pages 18190 - 18199, DOI: 10.1523/JNEUROSCI.1592-13.2013 *
R. M. KOFFIE ET AL: "Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging", PNAS, vol. 108, no. 46, (2011), pages 18837 - 18842, *
STARKEL P ET AL: "Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis" J OF HEPATOLOGY, vol. 43, no. 4, (2005), pages 687 - 695, *
SUN BAO-LIANG ET AL: "Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases", PROGRESS IN NEUROBIOLOGY (OXFORD), vol. 163, no. Sp. Iss. SI, April 2018 (2018-04-01), pages 118 - 143, XP002797338 *
Vulchanova L, et al., 'Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture', Molecular Pain, (2010); vol. 6: no. 31. doi: 10.1186/1744-8069-6-31 *

Also Published As

Publication number Publication date
JP2024099600A (ja) 2024-07-25
WO2020072357A1 (en) 2020-04-09
AU2019354965A1 (en) 2021-05-06
EP3860564A1 (en) 2021-08-11
US20220031867A1 (en) 2022-02-03
JP2022508609A (ja) 2022-01-19
KR20210100086A (ko) 2021-08-13
JP7611149B2 (ja) 2025-01-09
CA3115071A1 (en) 2020-04-09
CN113226283A (zh) 2021-08-06
US12311035B2 (en) 2025-05-27

Similar Documents

Publication Publication Date Title
AU2019354965B2 (en) Improvement of glymphatic delivery by manipulating plasma osmolarity
Zhang et al. Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment
Plog et al. Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain
US20220280423A1 (en) Glymphatic delivery by manipulating plasma osmolarity
Iliff et al. Cerebral arterial pulsation drives paravascular CSF–interstitial fluid exchange in the murine brain
Prakash et al. NLRP3 inflammasome-targeting nanomicelles for preventing ischemia–reperfusion-induced inflammatory injury
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
KR20180035209A (ko) 종양에 대한 활성제의 더 나은 전달 방법
Lai et al. Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles
KR20180035210A (ko) 활성제의 류마티즘 전달 방법
US8658614B2 (en) Aptamer-containing compositions and methods for targeting E-selectin
JP2015526471A (ja) アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
Cavaglia et al. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs
Chen et al. Targeted delivery of TAPI-1 via biomimetic nanoparticles ameliorates post-infarct left ventricle function and remodelling
WO2002078670A1 (en) Neuroprotectants formulations and methods
Nguyen et al. A review on nanosystem-based delivery of tofacitinib for enhanced treatment of autoimmune diseases and inflammation
Zhang et al. Concentration rather than dose defines the local brain toxicity of agents that are effectively distributed by convection-enhanced delivery
US20170360732A1 (en) Methods and Drug Therapies for Patency of Occluded Blood Vessels Following Angioplasty
HK40058950A (en) Improvement of glymphatic delivery by manipulating plasma osmolarity
WO2025186814A1 (en) Methods of treating mood disorders
US20240390281A1 (en) Lipocoacervates and methods of making and using same
Lu et al. Transformable nanoassembly of CXCL16 peptide-SN38 conjugate improves intratumor permeation and retention in peritoneal metastases
AU2009247971A1 (en) Set of antiangiogenic molecules and use thereof
KR20250133576A (ko) 연골 손상 치료용 약물 전달체 및 이를 이용한 연골 손상으로 인한 질병 예방 또는 치료용 약학적 조성물
JP2026510233A (ja) グリンパ－リンパ流出の改善

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)